MedPath

Effect of dose-escalation protocol for capecitabine on dose in 4th cycle of chemotherapy

Phase 2
Conditions
Patients whose age is above 18 years old who suffered from metastatic breast cancer, colorectal cancer, gastroesophageal adenocarcinoma, or gastric cancer indicated for capecitabine combination regimen and justified to use capecitabine
capecitabine
administration and dosage
Registration Number
TCTR20230407003
Lead Sponsor
principal investigator
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Terminated (Halted Prematurely)
Sex
All
Target Recruitment
18
Inclusion Criteria

Patients suffered from metastatic breast cancer, colorectal cancer, gastroesophageal adenocarcinoma, or gastric cancer indicated for capecitabine combination regimen and justified to use capecitabine attended to Medical Oncology outpatient department Srinagarind hospital from 20th July 2022 to 31st October 2022. Due to slow accrual, the inclusion period was amended to add period from 17th November 2022 to 31st December 2022. The Eastern Cooperative Oncology Group performance status must be 0 or 1 and adequate organ function was required. Women of childbearing age and potential must have negative pregnancy test result and have adequate contraception.

Exclusion Criteria

Patients with incomplete recovery from surgery (if done), patient with resectable metastasis colorectal cancer, history of other malignancies within 5 years, any concomitant use of other investigational agents during the study treatment period, history of capecitabine allergy, pregnancy, breast-feeding, concomitant use of vitamin K antagonist or uncontrolled medical conditions judged by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
dose of capecitabine at 4th cycle at initial of 4th cycle of treatment Record the dose prescribed by physician (divided dose by patient's body surface area; record for 4 digits without decimal) for assessment of noninferiority of mean difference between two group
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath